Recent News

• 04.17.2025 - Adicet Bio Appoints Michael Grissinger to the Board of Directors
• 04.17.2025 - Adicet Bio Appoints Michael Grissinger to the Board of Directors
• 03.31.2025 - Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.31.2025 - Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.31.2025 - Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
• 03.31.2025 - Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
• 03.06.2025 - Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
• 03.06.2025 - Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
• 03.03.2025 - Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting
• 03.03.2025 - Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Recent Filings

• 04.11.2025 - 8-K Current report
• 03.26.2025 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 03.18.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.14.2025 - EFFECT Notice of Effectiveness
• 03.12.2025 - CORRESP Correspondence
• 03.11.2025 - UPLOAD SEC-generated letter
• 03.06.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.06.2025 - S-3 Registration statement under Securities Act of 1933
• 03.06.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.06.2025 - 8-K Current report